Nanobiotechnological Nanocapsules Containing Polyhemoglobin-Tyrosinase : Effects on Murine B16F10 Melanoma Cell Proliferation and Attachment

Abstract EN

We have reported previously that daily intravenous infusions of a soluble nanobiotechnological complex, polyhemoglobin-tyrosinase [polyHb-Tyr], can suppress the growth of murine B16F10 melanoma in a mouse model.

In order to avoid the need for daily intravenous injections, we have now extended this further as follows.

We have prepared two types of biodegradable nanocapsules containing [polyHb-Tyr].

One type is to increase the circulation time and decrease the frequency of injection and is based on polyethyleneglycol-polylactic acid (PEG-PLA) nanocapsules containing [polyHb-Tyr].

The other type is to allow for intratumoural or local injection and is based on polylactic acid (PLA) nanocapsules containing [polyHb-Tyr].

Cell culture studies show that it can inhibit the proliferation of murine B16F10 melanoma cells in the “proliferation model”.

It can also inhibit the attachment of murine B16F10 melanoma cells in the “attachment model.” This could be due to the action of tyrosinase on the depletion of tyrosine or the toxic effect of tyrosine metabolites.

The other component, polyhemoglobin (polyHb), plays a smaller role in nanocapsules containing [polyHb-Tyr], and this is most likely by its depletion of nitric oxide needed for melanoma cell growth.